133 related articles for article (PubMed ID: 33889549)
1. CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism.
Abudureheman T; Xia J; Li MH; Zhou H; Zheng WW; Zhou N; Shi RY; Zhu JM; Yang LT; Chen L; Zheng L; Xue K; Qing K; Duan CW
Front Oncol; 2021; 11():663360. PubMed ID: 33889549
[TBL] [Abstract][Full Text] [Related]
2. CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer.
Zhong S; Zhang Y; Yin X; Di W
Onco Targets Ther; 2019; 12():2137-2147. PubMed ID: 30962695
[TBL] [Abstract][Full Text] [Related]
3. Converged DNA Damage Response Renders Human Hepatocellular Carcinoma Sensitive to CDK7 Inhibition.
Xie G; Zhu A; Gu X
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406486
[TBL] [Abstract][Full Text] [Related]
4. THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
Cheng ZJ; Miao DL; Su QY; Tang XL; Wang XL; Deng LB; Shi HD; Xin HB
Acta Pharmacol Sin; 2019 Jun; 40(6):814-822. PubMed ID: 30446732
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
Ge H; Yao Y; Jiang Y; Wu X; Wang Y
Oral Dis; 2022 Apr; 28(3):611-620. PubMed ID: 33503275
[TBL] [Abstract][Full Text] [Related]
6. CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism.
Huang WL; Abudureheman T; Xia J; Chu L; Zhou H; Zheng WW; Zhou N; Shi RY; Li MH; Zhu JM; Qing K; Ji C; Liang KW; Guo S; Yin G; Duan CW
Front Cell Dev Biol; 2021; 9():641271. PubMed ID: 33748130
[TBL] [Abstract][Full Text] [Related]
7. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY
ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985
[TBL] [Abstract][Full Text] [Related]
8. CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine
Zhang S; Feng R; Bai J; Ning S; Xu X; Sun J; Wu M; Liu H
Leuk Lymphoma; 2023 Mar; 64(3):639-650. PubMed ID: 36657437
[TBL] [Abstract][Full Text] [Related]
9. THZ1, a covalent CDK7 inhibitor, enhances gemcitabine-induced cytotoxicity via suppression of Bcl-2 in urothelial carcinoma.
Kuo KL; Lin WC; Liu SH; Hsu FS; Kuo Y; Liao SM; Yang SP; Wang ZH; Hsu CH; Huang KH
Am J Cancer Res; 2021; 11(1):171-180. PubMed ID: 33520367
[TBL] [Abstract][Full Text] [Related]
10. Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation.
Ma X; Kuang X; Xia Q; Huang Z; Fan Y; Ning J; Wen J; Zhang H; Yan J; Zhang Q; Shen H; Long C
J Cancer; 2018; 9(17):3149-3155. PubMed ID: 30210638
[TBL] [Abstract][Full Text] [Related]
11. Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer.
Zhou Y; Lu L; Jiang G; Chen Z; Li J; An P; Chen L; Du J; Wang H
Cell Death Differ; 2019 Aug; 26(8):1442-1452. PubMed ID: 30451989
[TBL] [Abstract][Full Text] [Related]
12. SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer.
Tang L; Jin J; Xu K; Wang X; Tang J; Guan X
Oncogenesis; 2020 May; 9(5):47. PubMed ID: 32398735
[TBL] [Abstract][Full Text] [Related]
13. Effect of CDK7 inhibitor on MYCN-amplified retinoblastoma.
Xu H; Xiao L; Chen Y; Liu Y; Zhang Y; Gao Y; Man S; Yan N; Zhang M
Biochim Biophys Acta Gene Regul Mech; 2023 Sep; 1866(3):194964. PubMed ID: 37536559
[TBL] [Abstract][Full Text] [Related]
14. Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1.
Wang Y; Zhang Z; Mi X; Li M; Huang D; Song T; Qi X; Yang M
Cell Commun Signal; 2022 Sep; 20(1):96. PubMed ID: 36058938
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma.
Chen HD; Huang CS; Xu QC; Li F; Huang XT; Wang JQ; Li SJ; Zhao W; Yin XY
Int J Biol Sci; 2020; 16(7):1207-1217. PubMed ID: 32174795
[TBL] [Abstract][Full Text] [Related]
16. Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis.
Zhang MY; Liu SL; Huang WL; Tang DB; Zheng WW; Zhou N; Zhou H; Abudureheman T; Tang ZH; Zhou BS; Duan CW
Med Sci Monit; 2020 Apr; 26():e923411. PubMed ID: 32266878
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer.
Wang J; Li Z; Mei H; Zhang D; Wu G; Zhang T; Lin Z
Anticancer Drugs; 2019 Jun; 30(5):466-474. PubMed ID: 30694816
[TBL] [Abstract][Full Text] [Related]
18. Targeting transcriptional kinase of CDK7 halts proliferation of multiple myeloma cells by modulating the function of canonical NF-kB pathway and cell cycle regulatory proteins.
Dutta RP; Kumar R; Tembhare PR; Bagal B; Swain RK; Hasan SK
Transl Oncol; 2023 Sep; 35():101729. PubMed ID: 37369156
[TBL] [Abstract][Full Text] [Related]
19. Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition.
Peng J; Yang M; Bi R; Wang Y; Wang C; Wei X; Zhang Z; Xie X; Wei W
Front Oncol; 2021; 11():664848. PubMed ID: 34109118
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma.
Greenall SA; Lim YC; Mitchell CB; Ensbey KS; Stringer BW; Wilding AL; O'Neill GM; McDonald KL; Gough DJ; Day BW; Johns TG
Oncogenesis; 2017 May; 6(5):e336. PubMed ID: 28504693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
